PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
6.22%
Cash & equivalents yoy growth below half of RVPH's 95.93%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
-100.00%
Both RVPH and the company show zero Short-Term Investments Growth.
6.22%
Below half of RVPH's 95.93%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x RVPH's -54.11%. Michael Burry might investigate for potential short-term asset misclassification or risk.
13.80%
Below half of RVPH's 72.84%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
2.11%
Higher PP&E (Net) Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.11%
Higher Total Non-Current Assets Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
13.78%
Below half of RVPH's 64.40%. Michael Burry sees a potential red flag for stagnation or capital shortage.
62.36%
Above 1.5x RVPH's 5.25%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-40.14%
Similar yoy changes to RVPH's -49.51%. Walter Schloss finds a parallel approach to short-term funding.
No Data
No Data available this quarter, please select a different quarter.
133.46%
Higher Deferred Revenue (Current) Growth compared to RVPH's zero value, indicating better performance.
184.58%
Exceeding 1.5x RVPH's 8.21%. Michael Burry suspects ballooning short-term obligations vs. competitor.
173.41%
Above 1.5x RVPH's 4.94%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
173.41%
Above 1.5x RVPH's 4.83%. Michael Burry sees a potential leverage warning sign.
4.06%
Less than half of RVPH's 45.49%. David Dodd sees fewer share issuances vs. competitor.
-25.11%
≥ 1.5x RVPH's -3.55%. David Dodd sees higher yoy retained profits than competitor.
-90.06%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to RVPH's zero value, indicating worse performance.
-763.59%
Below half RVPH's 89.71%. Michael Burry sees potential underperformance in building shareholder capital.
13.78%
Below half RVPH's 64.40%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both RVPH and the company show zero Total Investments Growth.
-40.14%
Similar yoy changes to RVPH's -49.51%. Walter Schloss notes parallel total debt strategies.
-7.59%
Less than half of RVPH's -102.37%. David Dodd sees better deleveraging or stronger cash buildup than competitor.